New Drugs and Devices for HF Therapy
Published: 31 July 2020
-
Views:
297
-
Likes:
7
-
Views:
297
-
Likes:
7
-
15m 37s
-
15m 47s
-
14m 16s
Overview
This session was part of the 1st e-SPACE Heart Failure Meeting held virtually on July 11-14th 2020 and focuses on novel drugs and devices changing the treatment paradigm in Heart Failure management.
Agenda
- Omecamtiv Mecarbil for Chronic HF - John Teerlink (University of San Francisco, San Francisco, US)
- Devices for Functional MR beyond Mitraclip - Ralph Stephan von Bardeleben (University of Mainz, Mainz, DE)
- Devices for Baroreflex Stimulation - Andrew Coats (Monash University, Melbourne, AU)
- More on New Drugs and Devices on the Horizon - Stefan Anker (Charite University, Berlin, DE)
More from this programme
Part 1
Omecamtiv Mecarbil for Chronic HF
| 1 session | |
| Omecamtiv Mecarbil for Chronic HF | Watch now |
Part 2
Devices for Functional MR beyond Mitraclip
Part 3
Devices for Baroreflex Stimulation
| 1 session | |
| Devices for Baroreflex Stimulation | Watch now |
Part 4
More on New Drugs and Devices on the Horizon
Faculty Biographies
John R Teerlink
Director
Dr John R Teerlink is Director of the Heart Failure Program and of the Clinical Echocardiography Laboratory at the San Francisco Veterans Affairs Medical Center in San Francisco, California.
Dr Teerlink graduated from Swarthmore College with Highest Honors in Comparative Religious Studies and Cellular Biology. After receiving his medical degree from Harvard Medical School, he completed an internal medicine residency at the University of California San Francisco (UCSF).